Press Releases

November 15, 2019

Regulatory

SynAct Pharma publishes Q3 2019 interim report (in Swedish)

November 11, 2019

Non Regulatory

SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189

October 28, 2019

Non Regulatory

Redeye: Adding an indication

October 21, 2019

Regulatory

SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189

August 30, 2019

Regulatory

SynAct Pharma publishes Q2 2019 interim report (in Swedish)

May 2, 2019

Regulatory

SynAct Pharma AB secures bridge loan financing for AP1189

April 24, 2019

Regulatory

SynAct Pharma publishes Q1 2019 interim report (in Swedish)

April 17, 2019

Regulatory

SynAct publishes annual report and consolidated accounts for 2018

April 9, 2019

Regulatory

Notice of Annual General Meeting of SynAct Pharma AB

March 29, 2019

Regulatory

SynAct applies for start of phase IIa clinical study in patients with active arthritis

March 21, 2019

Regulatory

Bulletin from the Extraordinary General Meeting at SynAct Pharma AB

February 25, 2019

Non Regulatory

John Haurum and Terje Kalland are proposed as new members of the Board of Directors in SynAct Pharma AB

February 19, 2019

Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

February 13, 2019

Regulatory

Changes in the Board of Directors of SynAct Pharma

February 11, 2019

Regulatory

Year-end report for the financial year 2018

February 11, 2019

Regulatory

SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes